EUROPEAN PATENT SPECIFICATION

Date of publication of patent specification: 20.07.94
Int. Cl.5: A61K 9/22, A61K 9/24

Application number: 90107877.4

Date of filing: 25.09.86

Publication number of the earlier application in accordance with Art.76 EPC: 0 218 148

Slow-release pharmaceutical composition.

Priority: 26.09.85 JP 213277/85

Date of publication of application: 12.09.90 Bulletin 90/37

Publication of the grant of the patent: 20.07.94 Bulletin 94/29

Designated Contracting States: AT BE CH DE FR GB IT LI LU NL SE

References cited:
EP-A- 0 123 470
EP-A- 0 185 347
GB-A- 1 037 689
GB-A- 2 123 291
US-A- 3 577 491

Proprietor: Chugai Selyaku Kabushiki Kaisha
5-1, 5-chome, Ukima
Kita-ku
Tokyo(JP)

Inventor: Iida, Yoshimitsu
2-15-1-915, Shirako
Wako-shi, Saitama-ken(JP)
Inventor: Sumida, Shuji
Sanhatsu 301,
1-26-20, Kitahara-cho
Tanashi-shi, Tokyo(JP)

Representative: VOSSIUS & PARTNER
Postfach 86 07 67
D-81634 München (DE)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).
Description

While many compounds are known to be useful as pharmacologically active substances, some of them have a relatively short biological half life and must be administered several times a day in order to exhibit their full action. However, a decrease in the number of administrations will not only reduce the burden on the patient but will also increase his compliance and thus provide greater therapeutic effects. In order to meet this requirement, medicines must release their active ingredients slowly so that they maintain effective levels in the blood for a prolonged period of time.

Various techniques have been proposed for preparing slow-release pharmaceutical compositions that are capable of retaining the concentrations of their active substances in the blood for a prolonged period of time. Most of the slow-release pharmaceuticals so far proposed employ a variety of high-molecular weight materials which include: hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl methyl cellulose phthalate, pullulan, gelatin, collagen, casein, agar, gum arabic, dextrin, ethyl cellulose, methyl cellulose, chitin, chitosan, mannan, carboxymethylthethyl cellulose, sodium carboxymethyl cellulose, polyethylene glycol, sodium alginate, poly(vinyl alcohol), cellulose acetate, poly(vinylpyrrolidone) silicone, poly(vinyl acetal) diethylamino acetate and albumin [see Sustained and Controlled Release Drug Delivery Systems, Marcel Dekker, Inc., 1978; Yakkyoku (Pharmacy), vol. 35, No. 2, pp 575 - 583, 1984; and Japanese Patent Public Disclosure No. 62521/1984].

The use of the above-listed high-molecular weight materials in manufacturing slow-release pharmaceuticals has several problems: (1) many high-molecular weight materials, particularly those which are soluble in water, have such a high moisture content that the pharmacologically active substances incorporated therein are liable to suffer decomposition, such as by hydrolysis, and often fail to withstand prolonged storage; (2) high-molecular weight materials have distributions in molecular weight and their molecular weight distribution and average molecular weight generally differ from one to another notwithstanding the existence of certain limits to be complied with and, therefore, the slow-release pharmaceuticals employing such high-molecular weight materials will experience considerable variations in the drug dissolution rate no matter how strict the quality control is during the manufacturing process; (3) some of the slow-release pharmaceuticals employing high-molecular weight materials are used while they are implanted in the human body, but many high-molecular weight materials are not decomposed in the human body at all or are decomposed only slightly, and therefore have to be removed from the human body after they have liberated the pharmacologically active substance; even the high-molecular weight materials that are decomposable in the human body are in most cases dependent on the presence of decomposition enzymes if the rate of their decomposition is to be satisfactory, and this applies to the rate of release of the active substance too; furthermore, even the decomposable high-molecular weight materials are not completely decomposed to monomers and there is a high possibility that only a part of them are decomposed, most of them remaining as polymers and being absorbed by tissues to become a potential antigen capable of causing an anaphylactic shock [see Seiyaku Kojo (Pharmaceutical Factory), vol. 13, No. 10, pp. 552 - 557 (1983); and Kagaku no Ryooki (Region of Chemistry), Special Issue, No. 134, pp. 151 - 157, Nankodo]; and (4) in slow-release pharmaceuticals of the matrix type and those wherein the active substances (i.e., drugs) are released through a semipermeable membrane, the drug release rate is so highly dependent on the solubility of the drug that such types of slow-release pharmaceuticals are not suitable for use with sparingly soluble drugs.

EP-A-0 123 470 discloses a sustained absorption propranolol-containing pellet for oral administration. The pellet comprises a core of propranolol or a pharmaceutically acceptable salt thereof and an organic acid which may be fumaric acid, embedded in a polymeric material in a multi-layer arrangement, and an outer membrane. The outer membrane which consists of a polymeric material is said to be responsible for the slow-release effect.

JP 265 888/84 discloses the process for producing stable tablets characterized by compressing an active ingredient and finely comminuted sugar. The use of fumaric acid is not disclosed in this document.

JP 149 688/85 discloses a process for producing a stable nicorandil containing pharmaceutical preparation characterized by mixing an organic acid such as fumaric acid with nicorandil. The combination of other drugs than nicorandil with fumaric acid is not disclosed in this document.

It is the object of the present invention to provide a pharmaceutical composition which will slowly release its active ingredient over a period of time and which is free from the aforementioned problems of the prior art products. This object could be achieved by the surprising finding that the duration of the sustained release of a pharmaceutically active substance can be extended significantly by employing fumaric acid which is a low-molecular weight material. However, it was found that no such prolonging effect could be attained by organic acids other than fumaric acid such as citric acid, maleic acid, succinic acid,
tartaric acid and malic acid.

The subject matter of the invention therefore is a slow-release pharmaceutical composition which comprises fumaric acid as a slow release inducing agent in addition to one or more pharmacologically active substances, provided that the combination of Nicorandil or propanolol or a pharmaceutically acceptable salt thereof and fumaric acid is excluded. Fumaric acid is present in an amount of at least 10 wt% of the total weight of the composition.

The slow-release pharmaceutical composition according to the invention may be a layered tablet consisting of a layer containing a pharmacologically active substance and a layer which does not contain any pharmaceutically active substance.

A slow-release multiple layered tablet of the invention may be prepared by compressing a layer having the composition recited above and a fast-release layer containing the same pharmacologically active substance as present in the first layer. Another slow-release multiple-layered tablet of the invention may be prepared by compressing a layer having the composition recited above, a layer composed of fumaric acid, and a fast-release layer containing the same pharmacologically active substance as present in the first layer.

A slow-release granule of the invention is composed of a granulation having the composition recited above. It may comprise in addition a fast-release granulation containing the same pharmacologically active substance as present in the first granulation. The slow-release granule composed of a granulation having the composition recited above can be coated with an enteric base or with a water-insoluble base. Also, the slow-release granule comprising the granulation having the composition recited above which is coated with an enteric base or with a water-insoluble base may comprise in addition a fast-release granulation containing the same pharmacologically active substance as present in the first granulation.

A further subject matter of the invention is a slow-release granule wherein a fast-release granulation of a pharmacologically active substance is coated with fumaric acid.

A further subject matter of the invention is a slow-release capsule which is filled with the slow-release granules having the composition recited above.

A further subject matter of the invention is a slow-release tablet prepared by compressing a powder or a granulation having the composition recited above. The slow-release tablet may also be prepared by compressing a mixture of a granulation having the composition recited above and a water-insoluble base.

A further subject matter of the invention is a slow-release tablet wherein a tablet prepared by compressing a granulation having the composition recited above or a powder having the composition recited above is coated with an enteric base.

Still a further subject matter of the invention is a slow-release tablet wherein a tablet prepared by compressing a granulation having the composition recited above or a powder having the composition recited above is coated with a water-insoluble base.

A sugar-coated slow-release tablet according to the invention is a tablet having the composition recited and being surrounded by a sugar coat. In another sugar-coated slow-release tablet of the invention a tablet having the composition recited above is surrounded by a sugar coating containing the same pharmacologically active substance as present in said coated tablet.

A core/shell slow-release tablet according to the invention has a core which is a tablet having the composition recited above with a shell being compressed around said core tablet, said shell being made of a fast-release composition containing the same pharmacologically active substance as present in said core tablet. In another core/shell slow-release tablet of the invention the core is a tablet having the composition recited above with two shells being compressed around said core tablet, the first shell around said core tablet being made of fumaric acid, and the second shell around said first shell being made of a fast-release composition containing the same pharmacologically active substance as present in said core tablet.

In a slow-release suppository of the invention a granulation having the composition recited above is incorporated in a suppository base. In another slow-release suppository of the invention a tablet having the composition recited above is coated with a suppository base.

Fig. 1 depicts the dissolution profile of the layered tablets prepared in the Example.

The slow-release pharmaceutical composition of the present invention is prepared by the following procedures: predetermined amounts of a pharmacologically active substance and an excipient are weighed; predetermined amounts of fumaric acid are weighed; and the individual components are mixed by a routine method. The use of an excipient is optional but if one is used, preferable excipients are lactose, mannitol, inositol, calcium citrate, dibasic calcium phosphate, hardened oils, and stearic acid. The desirable effect of fumaric acid is attained if the latter is used in an amount of at least 10% of the total weight of the pharmaceutical composition.
The slow-release pharmaceutical agent of the present invention may be used with practically all types of drugs such as hypotensives, antipyretic analgesic antiinflammatories, immunoregulators, adrenocortical hormones, anti-diabetic agents, vasodilators, cardiotonics, antiarrhythmic agents, anti-arteriosclerotic agents and antidotes.

To the mixed powder containing the pharmacologically active substance, fumaric acid and optionally an excipient, a lubricant such as magnesium stearate, calcium stearate or talc, and any other necessary components are added and the resulting mixture is compressed into tablets. If desired, the mixture may be worked into a dosage form suitable for implanting in the human body.

The mixed powder may also be blended with sucrose, a fragrance, a colorant and any other appropriate components and the resulting blend is then compressed to form troches of predetermined shapes. If desired, the blend may be formulated as a pharmaceutical for buccal administration.

A layer (A) containing a pharmaceutically active substance may be placed on another layer (B) containing no such active substance and the two layers are then compressed together to form a double-layered tablet which achieves enhanced delivery of the effective substance after a given period of time has passed. Two modifications of this multiple-layered tablet are as follows: a tablet which is prepared by compressing a layer having the composition specified by the present invention and a fast-release layer containing the same pharmacologically active substance; and a tablet prepared by compressing the following three layers:

the first layer having the composition specified by the present invention, the second layer consisting of fumaric acid, and the third layer being a fast-release layer containing a pharmacologically active substance which is the same as the one present in the first layer.

The mixed powder described above may be blended with an appropriate binder, such as hydroxypropyl cellulose, hydroxypropyl methyl cellulose or corn starch, dissolved in either water or an organic solvent, and the blend is granulated, dried and classified to obtain granules. If desired, a granulation having this composition may be mixed with a fast-release granulation containing the same pharmacologically active substance. Slow-release enteric granules may be prepared by coating the first granulation with enteric bases such as hydroxypropyl methyl cellulose phthalate and carboxymethylcellulose. These enteric slow-release granules may be mixed with fast-release granules containing the same pharmacologically active substance. Said first granulation may be coated with water-insoluble bases and the so coated granules may optionally be mixed with fast-release granules containing the same pharmacologically active substance. The fast-release granules containing a pharmacologically active substance may be coated with fumaric acid to convert them into slow-release granules. If desired, these slow-release granules may be compressed to form slow-release tablets. Mixtures of said granules with water-insoluble bases may be compressed into tablets and the so formed tablets may be coated with enteric bases or water-insoluble bases. These tablets may be provided with a sugar coating which may optionally contain a pharmacologically active substance of the same type as incorporated in the center of the tablets. Core/shell type slow-release tablets may be prepared by compressing the aforementioned tablets after they have been coated with a fast-release composition containing the same pharmacologically active substance. In this case, a coat of fumaric acid may be provided between the core and the shell of the fast-release composition. Any type of the aforementioned granules may be encapsulated to formulate capsules. If desired, the aforementioned slow-release granules may be incorporated in suppository bases to form slow-release suppositories. Alternatively, slow-release suppositories may be prepared by coating the aforementioned slow-release tablets with suppository bases.

The slow-release pharmaceutical composition of the present invention releases its active substance as the fumaric acid is slowly lost, so the pharmacologically active substance that can be incorporated may be water-soluble or sparingly water-soluble and is not limited to any particular type.

It should of course be understood that in putting the slow-release pharmaceutical composition of the present invention to use, colorants, flavoring agents, stabilizers and any other appropriate additives may be added as required.

The present invention is hereunder described in greater detail with reference to a working example, to which the scope of the invention is by no means limited.
Example

<table>
<thead>
<tr>
<th>Layered tablet</th>
<th>lower layer (mg)</th>
<th>middle layer (mg)</th>
<th>upper layer (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scopolamine hydrobromide</td>
<td>0.2</td>
<td>-</td>
<td>0.1</td>
</tr>
<tr>
<td>Fumaric acid</td>
<td>60</td>
<td>25</td>
<td>-</td>
</tr>
<tr>
<td>Calcium hydrogenphosphate (anhydrous)</td>
<td>29.4</td>
<td>9.8</td>
<td>-</td>
</tr>
<tr>
<td>Lactose</td>
<td>-</td>
<td>-</td>
<td>24.7</td>
</tr>
<tr>
<td>Crystalline cellulose</td>
<td>-</td>
<td>-</td>
<td>10</td>
</tr>
<tr>
<td>Calcium stearate</td>
<td>0.4</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>Total</td>
<td>90</td>
<td>35</td>
<td>35</td>
</tr>
</tbody>
</table>

To 0.2 g of scopolamine hydrobromide, 29.4 g of calcium hydrogenphosphate (anhydrous) was added in small portions and well mixed in a mortar to form a triturate. The triturate (29.6 g) was well mixed with fumaric acid (60 g) and calcium stearate (0.4 g) in a polyethylene bag to form a mixed powder A.

Twenty-five grams of fumaric acid, 9.8 g of potassium hydrogenphosphate (anhydrous) and 0.2 g of calcium stearate were intimately mixed in a polyethylene bag to make a mixed powder B.

To 0.1 g of scopolamine hydrobromide, 10 g of crystalline cellulose was added in small portions and mixed well in a mortar to make a triturate. This triturate (10.1 g) was well mixed with 24.7 g of lactose and 0.2 g of calcium stearate in a polyethylene bag to make a mixed powder C.

Multilayer tableting was performed on a single-punch machine equipped with a die (8 mm²) and flat-faced punches: first, 90 mg of the mixed powder A was placed in the die and precompressed lightly; 35 mg of the mixed powder B was placed on the first fill and lightly precompressed; thereafter, 35 mg of the mixed powder C was placed on the second fill and compressed with a total pressure of about 1.2 tons.

The resulting multi-layered tablets had the dissolution profile depicted in Fig. 1 that was obtained by conducting a dissolution test with an apparatus of the type specified in "Method I (rotary basket method)"; the Japanese Pharmacopoeia, 10th rev.; 500 ml of distilled water was used as a testing fluid and the basket was rotated at 100 rpm.

Claims

1. A slow-release pharmaceutical composition which comprises fumaric acid as a slow-release inducing agent in addition to one or more pharmacologically active substances whereby the fumaric acid is present in an amount of at least 10 wt. % of the total weight of the composition, provided that the combination of Nicorandil or propranolol or a pharmaceutically acceptable salt thereof and fumaric acid is excluded, which is a layered tablet consisting of a layer containing a pharmacologically active substance and a layer which does not contain any pharmacologically active substance.

2. A slow-release multiple-layered tablet which is obtainable by compressing a layer having the composition recited in Claim 1 and a fast-release layer containing the same pharmacologically active substance as present in the first layer.

3. A slow-release multiple-layered tablet which is obtainable by compressing a layer having the composition recited in Claim 1, a layer composed of fumaric acid and a fast-release layer containing the same pharmacologically active substance as present in the first layer.


5. A slow-release granule composed of a granulation having the composition recited in Claim 1 and which is coated with an enteric base or with a water-insoluble base.

6. A slow-release granule according to Claim 4 or 5 further comprising a fast-release granulation containing the same pharmacologically active substance as present in the first granulation.

7. A slow-release granule wherein a fast-release granulation of the pharmacologically active substance is coated with fumaric acid.
8. A slow-release capsule which is filled with granules having the composition recited in any one of Claims 4 to 7.

9. A slow-release tablet obtainable by compressing a powder having the composition comprising fumaric acid in an amount of at least 10 wt% of the total weight of the composition and in addition to one or more pharmaceutically active substances, provided that the combination of Nicorandil or propranolol or a pharmaceutically acceptable salt thereof and fumaric acid is excluded, or by compressing a granulation having the composition recited in any of Claims 4 to 7, or by compressing a mixture of a granulation having the composition recited in Claim 1 and a water-insoluble base.

10. A slow-release tablet wherein a tablet obtainable by compressing a granulation having the composition recited in Claim 4 or a powder having the composition recited in Claim 1 is coated with an enteric base or with a water-insoluble base.

11. A sugar-coated slow-release tablet wherein a tablet having the composition recited in any one of Claims 9 or 10 is surrounded by a sugar coating optionally containing the same pharmaceutically active substance as present in said center tablet.

12. A core/shell slow-release tablet wherein the core is a tablet having the composition recited in any one of Claims 9 or 10, with a shell being compressed around said core tablet, said shell being made of a fast-release composition containing the same pharmaceutically active substance as present in said core tablet.

13. A core/shell slow-release tablet wherein the core is a tablet having the composition recited in any one of Claims 9 or 10, with two shells being compressed around said core tablet, the first shell around said core tablet being made of fumaric acid and the second shell around said first shell being made of a fast-release composition containing the same pharmaceutically active substance as present in said core tablet.

14. A slow-release suppository wherein a granulation having the composition recited in any one of Claims 4 to 7 is incorporated in a suppository base, or a tablet having the composition recited in Claim 9 is coated with a suppository base.

15. The use of fumaric acid for preparing a slow-release pharmaceutical composition.

Patentansprüche

1. Arzneimittel mit langsamem Wirkstofffreisetzung, umfassend Fumarsäure als Induktionsmittel für die langsame Freisetzung, zusätzlich zu einem oder mehreren pharmakologischen Wirkstoffen, wobei die Fumarsäure in einer Menge von mindestens 10 Gew.-%, bezogen auf das Gesamtgewicht des Mittels, vorliegt, mit der Maßgabe, daß die Kombination von Nicorandil oder Propranolol oder eines pharmazeutisch verträglichen Salzes davon und Fumarsäure ausgeschlossen ist, das eine Schichttablette ist, die aus einer Schicht besteht, die einen pharmakologischen Wirkstoff enthält, und aus einer Schicht, die keinen pharmakologischen Wirkstoff enthält.


5. Granulum mit langsamer Wirkstofffreisetzung aus einem Granulat mit der in Anspruch 1 angeführten Zusammensetzung, das mit einem darmlösenderen oder einem wasserunlöslichen Grundstoff überzogen ist.


8. Kapsel mit langsamer Wirkstofffreisetzung, die gefüllt ist mit Granula, die in einem der Ansprüche 4 bis 7 angeführten Zusammensetzung aufweisen.


10. Tablette mit langsamer Wirkstofffreisetzung, wobei eine Tablette, die erhältlich ist durch Pressen eines Granulats mit der in Anspruch 4 angeführten Zusammensetzung oder eines Pulvers mit der in Anspruch 1 angeführten Zusammensetzung mit einem darmlösenden oder einem wasserunlöslichen Grundstoff überzogen ist.


15. Verwendung von Fumarsäure für die Herstellung eines Arzneimittels mit langsamer Wirkstofffreisetzung.

Revendications

1. Composition pharmaceutique à libération lente qui comprend de l'acide fumarique comme agent induisant la libération lente en plus d'une ou de plusieurs substances pharmaco logiquement actives, dans laquelle l'acide fumarique est présent en une quantité d'au moins 10% en poids du poids total de la composition, à la condition que la combinaison de Nicorandil ou de propranolol ou d'un de leurs sels
pharmaceutiquement acceptables et d'acide fumarique soit exclue, qui est un comprimé en couches consistant en une couche contenant une substance pharmaceutiquement active et en une couche ne contenant pas de substance pharmaceutiquement active.

2. Comprimé multicouche à libération lente qui peut être obtenu par compression d'une couche ayant la composition donnée à la revendication 1 et d'une couche à libération rapide contenant la même substance pharmaceutiquement active que celle présente dans la première couche.

3. Comprimé multicouche à libération lente qui peut être obtenu par compression d'une couche ayant la composition donnée à la revendication 1, d'une couche composée d'acide fumarique et d'une couche à libération rapide contenant la même substance pharmaceutiquement active que celle présente dans la première couche.

4. Granule à libération lente composé d'une granulation ayant la composition donnée à la revendication 1.

5. Granule à libération lente composé d'une granulation ayant la composition donnée à la revendication 1 et qui est enveloppé d'une base keratinisée ou d'une base insoluble dans l'eau.

6. Granule à libération lente suivant la revendication 4 ou 5, comprenant de plus une granulation à libération rapide contenant la même substance pharmacologiquement active que celle présente dans la première granulation.

7. Granule à libération lente dans lequel une granulation à libération rapide de la substance pharmacologiquement active est enveloppée d'acide fumarique.

8. Capsule à libération lente qui est remplie de granules ayant la composition donnée à l'une quelconque des revendications 4 à 7.

9. Comprimé à libération lente qui peut être obtenu par compression d'une poudre ayant la composition comprenant de l'acide fumarique en une quantité d'au moins 10% en poids du poids total de la composition et en plus, d'une ou de plusieurs substances pharmacologiquement actives, à la condition que la combinaison de Nicorandil ou de propanolol ou de un de leurs sels pharmaceutiquement acceptables et d'acide fumarique soit exclue, ou par compression d'une granulation ayant la composition donnée à l'une quelconque des revendications 4 à 7 ou par compression d'un mélange d'une granulation ayant la composition donnée à la revendication 1 et d'une base insoluble dans l'eau.

10. Comprimé à libération lente dans lequel un comprimé susceptible d'être obtenu par compression d'une granulation ayant la composition donnée à la revendication 4 ou d'une poudre ayant la composition donnée à la revendication 1, est enveloppé d'une base keratinisée ou d'une base insoluble dans l'eau.

11. Comprimé à libération lente enrobé de sucre dans lequel un comprimé ayant la composition donnée à l'une quelconque des revendications 4 ou 10, est entouré d'un revêtement de sucre contenant facultativement la même substance pharmacologiquement active que celle présente dans le centre du comprimé.

12. Comprimé à libération lente coeur/coquille dans lequel le cœur est un comprimé ayant la composition donnée à l'une quelconque des revendications 9 ou 10, avec une coquille comprimée autour du cœur du comprimé, la coquille étant faite d'une composition à libération rapide contenant la même substance pharmacologiquement active que celle présente dans le cœur du comprimé.

13. Comprimé à libération lente coeur/coquille dans lequel le cœur est un comprimé ayant la composition donnée à l'une quelconque des revendications 9 ou 10, avec deux coquilles comprimées autour du cœur, la première coquille autour du cœur étant faite d'acide fumarique et la deuxième coquille autour de la première coquille étant faite d'une composition à libération rapide contenant la même substance pharmacologiquement active que celle présente dans le cœur du comprimé.

14. Suppositoire à libération lente dans lequel une granulation ayant la composition donnée à l'une quelconque des revendications 4 à 7 est incorporée dans une base de suppositoire ou un comprimé
EP 0 386 801 B1

ayant la composition donnée à la revendication 9 est enrobé d'une base de suppositoire.

15. Utilisation d'acide fumarique dans la préparation d'une composition pharmaceutique à libération lente.
Fig. 1